PTK/ZK (Novartis)
- PMID: 12917775
PTK/ZK (Novartis)
Abstract
PTK/ZK, a VEGF receptor tyrosine kinase inhibitor, is under development by Novartis AG and Schering AG as an inhibitor of angiogenesis for the potential treatment of various cancers.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources